Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Questcor Pharmaceuticals Inc    QCOR

Delayed Quote. Delayed  - 08/14 10:00:01 pm
93.6 USD   +1.65%
2014DJJOHN PAULSON : Paulson & Co. Opens Positions in Covidien, DirecTV an..
2014DJGreenlight Notes Short Positions in Safeway, Lorillard -Reuters
2014 QUESTCOR PHARMA : Pre-Market Pulse on Health Care Stocks -- Research..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Questcor Pharmaceuticals, Inc. : Questcor Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/03/2013 | 12:35pm CEST

ANAHEIM, Calif., Jan. 3, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Thursday, January 10, 2013 at 9:00 a.m. PT / 12:00 p.m. ET.

A live webcast with accompanying slide presentation, and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor's primary product is H.P. Acthar(®) Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has also launched a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.

SOURCE Questcor Pharmaceuticals, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on QUESTCOR PHARMACEUTICALS I
2014DJJOHN PAULSON : Paulson & Co. Opens Positions in Covidien, DirecTV and Allergan
2014DJGreenlight Notes Short Positions in Safeway, Lorillard -Reuters
2014 QUESTCOR PHARMACEUTICALS : Pre-Market Pulse on Health Care Stocks -- Research on..
2014 QUESTCOR PHARMACEUTICALS INC : ex-dividend day
2014 QUESTCOR PHARMACEUTICALS : Closes Transaction to Acquire International Rights to..
2014 QUESTCOR PHARMACEUTICALS : Provides Support to Lupus Foundation of America Aware..
2014 QUESTCOR PHARMACEUTICALS : Receives "Recognition of Appreciation" Award from MS ..
2014 QUESTCOR PHARMACEUTICALS : Enters Into Development Collaboration Agreement Cover..
2014 Factbox - M&A frenzy transforming global pharma
2014 M&A frenzy in healthcare sector
More news
Sector news : Biopharmaceuticals
10:26aDJNOVO NORDISK A/S : to Cut 1,000 Jobs Amid Growing Competition -- Update
09/28DJINTRA CELLULAR THERAPIES : Shares Plunge After Disappointing Drug Trial Results
09/28DJGLAXOSMITHKLINE : to Sell Remaining 6.2% Stake in Aspen Pharmacare
09/28 Monsanto ally Novozymes sees opportunity, risk in Bayer merger
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
More sector news : Biopharmaceuticals